Loading clinical trials...
Loading clinical trials...
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LUCAR-20SP, an Allogenic Chimeric Antigen Receptor(CAR)-T Cell Therapy Targeting CD20 in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Conditions
Interventions
LUCAR-20SP cells
Locations
3
China
Beijing GoBroad Boren Hospital
Beijing, Beijing Municipality, China
Peking University Cancer Hospital & Institute
Beijing, Beijing Municipality, China
Henan Cancer Hospital
Zhengzhou, China
Start Date
March 14, 2024
Primary Completion Date
September 1, 2026
Completion Date
September 1, 2028
Last Updated
March 25, 2025
NCT07523555
NCT05272384
NCT06189391
NCT05583149
NCT04447716
NCT02628405
Lead Sponsor
Peking University Cancer Hospital & Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions